{"nctId":"NCT00456807","briefTitle":"Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years","startDateStruct":{"date":"2007-04"},"conditions":["Infections, Papillomavirus"],"count":100,"armGroups":[{"label":"Cervarix Group","type":"EXPERIMENTAL","interventionNames":["Biological: Cervarix TM"]},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Cervarix TM","otherNames":["GSK Biologicals' HPV-16/18 VLP/AS04 vaccine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A female enrolled in study 104820 and who received three doses of study vaccine/control.\n* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.\n* Written informed consent obtained from the subject prior to enrolment in this ancillary study.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Administration of any HPV vaccine other than that foreseen by the study protocol.\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine since study start.\n* Chronic administration of immunosuppressants or other immune-modifying drugs since study start.\n* Administration of immunoglobulins and/or any blood products within 90 days preceding a blood sampling.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"26 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Cytokine-positive CD4/CD8 Cells Per Million in Tests Producing at Least 2 Different Cytokines","description":"The geometric mean and 95% confidence interval of the number of Human Papilloma Virus type 16 (HPV-16) and HPV-18 specific CD4 and CD8 cells producing at least 2 different cytokines is reported per million of CD4 or CD8 T-cells, respectively.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"877.4","spread":null},{"groupId":"OG001","value":"19.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"738.5","spread":null},{"groupId":"OG001","value":"22.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"581.2","spread":null},{"groupId":"OG001","value":"11.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"300.1","spread":null},{"groupId":"OG001","value":"16.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"4.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of B-cells Per Million Showing a Specific Memory Response for HPV-16 and HPV-18","description":"The geometric mean and 95% confidence interval of the number of HPV-16 and HPV-18 specific memory B-cells is reported per million of B-cells.\n\nAn arbitrary value of 0 was given for subjects with antibody concentration below the limit of quantification.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"517.1","spread":null},{"groupId":"OG001","value":"101.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"304.4","spread":null},{"groupId":"OG001","value":"33.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"354.7","spread":null},{"groupId":"OG001","value":"68.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"301.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations Above Pre-defined Cut-off Values","description":"Cut-off values assessed include 8 enzyme-linked immunosorbent assay units Per Milliliter (EL.U/mL)for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"PRIMARY","title":"Titers of Anti-HPV-16 and Anti-HPV-18 Antibodies","description":"Titers are presented as Geometric Mean Titers (GMTs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2050.4","spread":null},{"groupId":"OG001","value":"6.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1517.1","spread":null},{"groupId":"OG001","value":"7.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"761.4","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"551.4","spread":null},{"groupId":"OG001","value":"4.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) Immunoglobulin G (IgG) Antibodies","description":"Titers given as Geometric Mean Titers (GMTs). An arbitrary value of 0 was given for subjects with antibody concentration below the limit of quantification.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"129.5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.9","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.8","spread":null},{"groupId":"OG001","value":"5.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Correlation of Anti-HPV-16 and Anti-HPV-18 Antibodies in Serum and in Cervical Secretion (CVS) Samples","description":"Pearson coefficients of correlation between serum and CVS for anti-HPV-16 and anti-HPV-18 titers standardized for total IgG were calculated.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.903","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.898","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.901","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.876","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":[]}}}